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Background. Wearable cardioverter-deﬁbrillators (WCD, LifeVest, ZOLL) can protect from sudden cardiac death bridging a
vulnerable period until a decision on implantable cardioverter-deﬁbrillator (ICD) implantation can be reached. WCD is
commonly used for 3 months or less. It is unknown, which patients use WCD longer and which patients are most likely to beneﬁt
from it.Hypothesis. Extended use ofWCD is reasonable in selected cases based on underlying heart disease and overall patient risk
proﬁle.Methods. We conducted a systematic and comprehensive research of all published clinical studies on PubMed reporting on
the use of the WCD. Only original articles reporting on wear times and time to appropriate shocks were included in our analysis.
Results. +e search resulted in 127 publications. 14 parameters were reported necessary for inclusion in our analysis. Median wear
times ranged from 16 to 394 days. +e median wear time was especially long for patients suﬀering from nonischemic car-
diomyopathy (NICM) (range: 50–71 days) and speciﬁcally peripartum cardiomyopathy (PPCM) (120 days) and for heart
transplant candidates. +ere was a large variation of appropriate shocks according to indication for WCD use. In contrast to
NICM in general, the number of appropriate shocks was particularly high in patients with PPCM (0 in 254 patients and 5 in 49
patients, respectively). +e median and maximal time periods to the ﬁrst appropriate shock were longest in patients with PPCM
(median time to the ﬁrst appropriate shock: 68 days).Conclusions. Prolonged use ofWCD is not uncommon in available literature.
Patients suﬀering from NICM and speciﬁcally PPCM seem most likely to have longer therapy duration with WCD with success.
Careful patient selection for prolonged use may decrease the need for ICD implantation in the future; however, prospective data
are needed to conﬁrm this hypothesis.
1. Introduction
+e implantable cardioverter-deﬁbrillator has ﬁrmly
established itself as a treatment option for patients at high
risk for life-threatening ventricular tachyarrhythmias. In
fact, several large randomized-controlled studies have
supported its eﬃcacy in preventing sudden cardiac death
(SCD) and in reduction of mortality in patients with is-
chemic cardiomyopathy (ICM) and an ejection fraction (EF)≤35% at least 6 weeks after the ischemic event or
nonischemic cardiomyopathy (NICM) and an EF ≤35%
after at least 3 months of optimal medical therapy (OMT)
in primary prophylaxis [1–5]. +e place for ICDs in sec-
ondary prophylaxis is clear, and it is indicated when a
hemodynamically relevant tachycardia is diagnosed with-
out a reversible cause or within 48 hours of an ischemic
event [6–8]. Several controversies remain, however, re-
garding the optimal use of ICDs in primary prevention. In
particular, questions of risk stratiﬁcation, including the
optimal time point for implantation, are unresolved yet.
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Moreover, there are clinical scenarios where the use of an
implantable cardioverter-deﬁbrillator (ICD) is not
possible.
+e wearable cardioverter-deﬁbrillator is a noninvasive
device used temporarily for the prevention of SCD in
presumed high-risk patients, which do not meet ICD
implantation criteria on the basis of current guidelines. So
far, only one wearable cardioverter-deﬁbrillator (WCD) is
approved for clinical use (LifeVest, ZOLL, Pittsburgh,
Pennsylvania, USA). +e device is a wearable vest with
built-in electrodes for rhythm sensing, and pads in case a
shock must be delivered [9, 10]. +e WCD can detect
ventricular tachycardia and ventricular ﬁbrillation using an
algorithm based on programmable heart rate cut-oﬀ values
and ECG morphology analysis. Arrhythmia detection
initiates a series of warnings before treatment ensues
(Figure 1). Current recommendations, however, do not
specify on the suggestedWCD use duration except for ICM
(40 days) [5]. On the contrary, WCD use is only a tem-
porary protection against SCD. Prolonged use is deﬁned as
longer than the current recommended waiting period
before implantation of an ICD, which is 3 months in the
case of NICM and 40 days after the index event for ICM
[11].
+e aim of this study was to provide a systematic analysis
of the published data on WCD-recorded appropriate shocks
in diﬀerent patient cohorts for extended time periods. +e
focus of our investigation was device wear length and time to
the ﬁrst appropriate shock. Our goal was to provide an
overview of current data on prolongedWCD use in available
literature and point out speciﬁc populations which seem to
beneﬁt most from it.
2. Methods
Studies were identiﬁed searching PubMed from the start of
the database until the end of 2017 using the term “wearable
cardioverter deﬁbrillator” or “wearable cardioverter-de-
ﬁbrillator” and “wcd.” Only English-written articles were
considered. Abstracts of all search results were screened
and only original clinical studies, excluding case reports
and small case series with n< 10 patients, were analyzed. All
original articles examining the clinical use of WCD were
screened for baseline characteristics, number of appro-
priate shocks, available median and maximal WCD wear
times, for the median time to the ﬁrst appropriate shock,
and maximal time to the ﬁrst appropriate shock. Our
objective was to describe the prevalence of prolongedWCD
use and the possible beneﬁt of prolonged use. Prolonged
use was deﬁned based on current guidelines as longer than
the recommended waiting period to ICD implantation, if
indicated: 3 months in case of NICM and 40 days in case of
ICM. Since no randomized clinical trials are available on
this subject, only studies reporting either maximal wear
time or median and maximal time to the ﬁrst appropriate
shock were included in our study, thus providing a sum-
mary of prolonged use of WCD and its potential beneﬁt for
speciﬁc populations.
3. Results
+e PubMed search resulted in a total of 127 publications.
101 were either not clinical studies or did not report on
WCD use. +e remaining 26 articles were screened, and 15
publications met the inclusion criteria. One study was ex-
cluded because of conﬂicting numbers reported in the
dataset (the authors could not be reached for clariﬁca-
tion) [12]. Study selection is shown in a ﬂow chart in
Figure 2.
+e investigated 14 clinical studies were published
between 2010 and 2017 (Table 1). 12 studies were retro-
spective based on registries, and data were collected by the
manufacturer of the WCD device [13–24]. One study was a
prospective observational investigation [25], and one
study prescribed the WCD according to a prespeciﬁed
algorithm and prospectively followed the study population
[26]. Of the retrospective studies, one was labelled a review
[24], but also reported on WCD experiences in Germany
and fulﬁlled inclusion criteria. +e main inclusion crite-
rion in all studies was obviously WCD use, although the
indications for use were variable. Seven studies included
patients with any underlying heart disease as indication for
WCD use, although one only included young patients, one
only included patients of hemodialysis, and one examined
patients with device infection only. +e remaining ﬁve
studies included patients with peripartum cardiomyopathy
(PPCM), heart failure in general, and patients with ICM or
NICM (Table 1).
+e size of study populations ranged from 49 to 8453
patients in the investigated studies, and a total of 22908
patients were primarily reviewed for this analysis. All
studies reported the median wear time (in 3 studies mean
wear time [16, 21, 24]) ranging from 16 to 394 days and
numbers of appropriate shocks (ranging from 0 to 309).
Ten studies were reported on maximal wear time. 4 studies
reported both median and maximal time to the ﬁrst ap-
propriate shock.
+e prevalence of prolonged use was not speciﬁcally
reported in either of the studies, except for the study of
Lamichhane et al. which speciﬁcally only included long-term
WCD users [18]. However, since three studies reported
median wear times over 90 days and further six reported
median wear times over 40 days, depending on the un-
derlying condition prolonged use of WCD was highly
prevalent. +e shortest and longest median and maximal
wear times and the shortest and longest maximal time to the
ﬁrst shock are summarized in Table 2.
+e number of appropriate shocks per total study
population varied greatly among the diﬀerent indications.
+e highest rate observed was in patients on hemodialysis
(136 appropriate shocks in 75 patients) [21]. A high rate was
also observed in the study investigating patients with PPCM
(5 appropriate shocks in 49 patients) [16]. No appropriate
shocks were reported in one cohort with NICM, the only
underage cohort (≤18 years), and in a mixed cohort of
patients with heart failure [14, 19, 23]. Further study
characteristics are illustrated in Table 1.
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Figure 1: Ventricular ﬂutter and ﬁbrillation detected and appropriately terminated by a WCD in a patient.
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4. Discussion
We here provide the ﬁrst systematic review of published data
on prolongedWCDuse in clinical practice and patients most
likely to beneﬁt from it.
4.1. IschemicCardiomyopathy. From the published data, it is
evident that prolonged use of WCD was rarely reported in
patients with ICM and ejection fraction ≤35%. +is is not
surprising, considering current guidelines giving an IA in-
dication for ICD implantation 3 months after an MI or PCI/
CABG with persistent symptomatic systolic heart failure
based on the SCD-HeFT and MADIT-II trials [1, 2, 11]. Of
the reviewed studies investigating WCD use in patients
suﬀering from ICM, the majority report short median wear
times and short times to the ﬁrst appropriate shock. Epstein
et al. reported a median time to the ﬁrst appropriate shock of
just 9 days after the start of the WCD use, which lies within
the 40 days required by current guidelines before ICD
implantation [22].
Singh et al. however report that only half of all shocks
were in the ﬁrst 40 days after an index MI suggesting that
several cases of malignant arrhythmia occur after the initial
waiting period. +is diﬀerence to Epstein’s results cannot
clearly be explained, since EF and medication (including
antiarrhythmic drugs) were not universally reported.
Furthermore, the event rates diﬀered by a factor of 2 between
the two studies. Similar to what Singh et al. reported, ap-
propriate shocks reported after an ischemic event occurred
within 40 days in a European cohort investigated by Kondo
et al. (not fulﬁlling inclusion criteria for primary analysis of
this study) [27].
Lamichhane et al., on the contrary, speciﬁcally in-
vestigated the use of WCD beyond three months. In their
study population, 35% had ICM, and the main reason for
prolonged use was ongoing evaluation for ICD implanta-
tion. Only 6 patients received appropriate shocks in this
cohort, and the authors, however, did not report the time of
the events/shocks [18]. In light of this data, patients suﬀering
from ICM seldom beneﬁted from prolonged use of WCD.
On the contrary, WCD possibly has beneﬁts in the ﬁrst 40
days after MI where the risk of SCD is reported to be up to
5% [28]. +e recently published VEST [29]was the ﬁrst
randomized clinical trial assessing this question. +ey found
no beneﬁt in the prevention of SCD with the use of WCD in
addition to guideline-directed therapy in the early stages
after myocardial infarction, although therapy adherence was
low. +is result underscores the problem of patient selection
and ensuring compliance and adherence to therapy.
4.2. Nonischemic Cardiomyopathy. +e reported wear time
for NICM was generally longer compared to ICM in the
reviewed studies [13, 15, 19, 25, 30]. A direct comparison of
the ICM and NICM population was subject only in the study
of Singh et al. +ey noted that, within their total population,
the wear time was signiﬁcantly longer for NICM patients
compared to ICM patients. +e authors, however, did not
observe shocks in this cohort. Chung et al. also did not
report any shocks in the NICM subpopulation [15]. Wa¨ßnig
et al. found the longest wear times in the NICM subgroup
but also low rates of appropriate shock. +e WEARIT-II
study reported 927 patients with NICM andWCD use. +ey
report 1% arrhythmic events in this subpopulation, which
was similar to Singh et al. and Wa¨ßnig et al.’s data, and
signiﬁcantly less than for the ICM patient subpopulation.
In light of the DANISH study [31], the question arises
whether a prolonged waiting/risk stratiﬁcation period and
establishment of OMT is warranted in this subgroup, before
ICD implantation is considered. +e prolonged study spe-
ciﬁcally examined patients with HFrEF after 3 months of
WCD use with the goal of preventing unnecessary ICD
implantations. An extended therapy was used in patients
who did not yet have OMTor showed an improvement of EF
since previous visit but still had an EF ≤35%. At the end of
the follow-up (median 9months), 33% of patients showed an
improvement of EF to >35% [32]. +ey observed im-
provement more often in the NICM patients than ICM
patients.
A further analysis from the WEARIT-II registry in-
vestigated patients using the WCD beyond 90 days and
found a higher rate of extended use in NICM patients and
furthermore discovered a further improvement in EF and
thus obviating the need for an ICD in one-third of their
patient cohort [33]. So far, the optimal timing of ICD
127 PubMed results 
using search criteria
101 entries that are not
clinical studies or not
investigating WCD
26 clinical studies
15 clinical studies
11 studies not meeting
our inclusion criteria
14 studies in the final 
analysis
1 study reporting conflicting data
Figure 2: Study selection ﬂow chart. WCD � wearable car-
dioverter-deﬁbrillator.
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implantation in NICM patients is still under debate.
Whether prolongedWCD use in NICM patients is an option
to prevent unnecessary ICD implantations, while mini-
mizing the risk of sudden cardiac death remains an open
question [34–36]. Hopefully, the currently recruiting HF-
Opt trial (NCT03016754) examining EF improvement be-
yond 90 days of WCD use will hopefully provide some
additional information on this subject.
Another possible indication for WCD use is PPCM,
which however may have been reported in previous cohort
investigating NICM as well. Duncker et al. provided the
study examining only patients with PPCM [16]. +ey report
a high prevalence of appropriate shocks. In contrast, in a
study, Saltzberg et al. (not meeting inclusion criteria for
primary analysis) compared patients with PPCM to NICM
of other aetiology.+e 107 patients included in their analysis
wore the WCD 75 ± 81 days and had no events requiring
intervention from the device [37]. It is noteworthy that this
study was a retrospective analysis with patient inclusion
based on the International Classiﬁcation of Diseases coding
and not according to current ESC criteria which may explain
the much lower event rate compared to what Duncker et al.
reported from their prospective study. Although the few
other patient characteristics reported by all of the afore-
mentioned three studies were similar (age, baseline EF, and
parity), a more precise comparison is not feasible due to
pronounced diﬀerences in methodology, reported variables,
and outcome measures. Of note, another study reporting on
cases of PPCM also reported on a high rate of appropriate
shocks during prolonged wear time [38].
Current ESC guidelines recommend ICD implantation
following standard guidelines for NICM, but also refer to
WCD treatment (recommendation level class IIb). +is is
particularly noteworthy since EF recovery can be expected in
a high rate of PPCM patients [11].
4.3. WCD in Patients with Device Infection. Data regarding
WCD use and device removal were available in 6 studies,
while Tanawuttiwat et al. only examined this cohort
[13, 15, 20, 21, 24, 25]. +e largest number of patients ex-
amined was provided byWa¨ßnig et al. [13]. Compared to the
study of Ellenbogen et al. not meeting inclusion criteria for
primary analysis, the median wear time was comparable but
longer than what Tanawuttiwat et al. reported. Ellenbogen
et al. demonstrated that 22% of their patients wore theWCD
Table 2: Shortest and longest device parameters reported in the included studies.
Median wear time Maximal weartime Median time to the ﬁrst appropriate shock Maximal time to the ﬁrst appropriate shock
Shortest 16 163 9 30
Longest 394 >7 years 68 >9 months
Table 1: Studies reviewed.
Year Author Indication n
Median
wear
time
Maximal
wear
time
Number of
appropriate
shocks
Median time to the
ﬁrst
appropriate shock
Maximal time to the
ﬁrst
appropriate shock
2010 Collins et al. [14]
Any (≤18 years of
age) 81 29 531 0 No shocks No shocks
Any (18–21 years
of
age)
103 35 499 5 ∗ ∗
2010 Chung et al. [15] Any 3569 36 1590 80 ∗ ∗
2010 Klein et al. [24] Any 354 106a >7 years 21 ∗ ∗
2010 Dillon et al. [17] Any 2105 36 365 54 ∗ ∗
2012 Kao et al. [23] Heart failureb 82 64 277 0 No shocks No shocks
2013 Epstein et al. [22] ICM 8453 57 ∗ 309 9 >9 months
2014 Wan et al. [21] Hemodialysedpatientsc 75 62.9
a 308 136 ∗ ∗
2014 Tanawuttiwat et al.[20] Device infection 97 21
d ∗ 4 23 38
2015 Singh et al. [19] ICM 271 53
∗ 6 34 45
NICM 254 71 ∗ 0 No shocks No shocks
2016 Lamichhane et al.[18] HFrEF
e 220 394 2013 13 ∗ ∗
2016 Wa¨ßnig et al. [13] Any 6043 59 163 ∗f ∗ ∗
2017 Erath et al. [25] Any 1102 54 166 8 ∗ ∗
2017 Sasaki et al. [26] Any 50 16 171 6 12 30
2017 Duncker et al. [16] PPCM 49 120a ∗ 5 68 124g
aReported as a mean; bdeﬁned by own speciﬁc criteria; conly patients with SCD events included; dmedian calculated for only 80 study patients; ewear time
always >90 days; f89% of treatments occurred in the ﬁrst 90 days; gcalculated from the time of diagnosis and not from the beginning of device therapy; ∗not
reported. Time is presented in days.
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for over 3 months without reporting on the indication for
this [39]. For obvious reasons, a prolonged wear time is only
necessary in selected cases since the indication for ICD
implantation has previously beenmade. Still an extended use
is clearly indicated until the infection abates and surgery is
again possible.
4.4. Heart Transplantation. Bridging the time to heart
transplantation is another possible indication for WCD use
[23, 24]. Although the reported number of appropriate
shocks was low, since the perioperative risk of ICD im-
plantation is especially high, these patients could especially
beneﬁt from extended WCD use. +e ESC guidelines rec-
ommend an ICD implantation for all patients listed for
transplant in a New York Heart Association class IV,
whereas WCD use as a bridge to transplant is an alternative
(recommendation level class IIa and IIb, respectively). In our
opinion, extended wear for secondary prophylaxis of SCD is
also an option in these patients.
4.5. Renal Failure. +ere are other, less frequent indications
for WCD use. Wan et al. investigated patients on hemodi-
alysis [21]. +is patient group is not included in most pivotal
ICD trials.+ey found that the main reason forWCD use was
active infection and contraindication for ICD implant in this
cohort, but they also pointed out that majority of patients
used the device for an extended period of time until EF
improvement or ICD implantation. Patients with end-stage
renal disease represent a high-risk population for ICD im-
plantation explaining the impressively high prevalence of
arrhythmic events during the study period. Nevertheless, the
same guidelines apply for ICD implantation in these patients
as for the general population. +us, prolonged WCD use was
only considered in few cases in available literature.
4.6. Myocarditis. Myocarditis was infrequent in the
reviewed studies. Only two studies were reported on wear
time [13, 25]. +e current ESC guidelines give a weak
recommendation for the use of WCD in these patients,
similar to the PPCM population. Given the excellent long-
term outcome of patients with myocarditis who recover
from the impaired cardiac function, prolonged WCD use
may be reasonable in this population.
4.7. Inherited Channelopathies. Few patients with channe-
lopathies or congenital heart diseases were included in the
assessed studies [15, 24, 25]. It seems prudent to thoroughly
evaluate these patients before ICD implantation, while
protecting them from SCD if necessary. To facilitate a safe
risk stratiﬁcation, WCD might be an option. Depending on
the phenotype of underlying disease, this stratiﬁcation pe-
riod can be rather long depending on clinical judgment.
4.8. Children and Adolescent. Another population who may
beneﬁt from an extended use of WCD is children and
younger adults. While they may have the highest lifetime
beneﬁt of an ICD implantation if indication is made cor-
rectly, they are also at higher risk of ICD complications such
as multiple battery changes and thus increased risk of in-
fection. Collins et al. examined a population ≤21 years of age
with a WCD use for any indication. +e main causes of
increased arrhythmogenic risk were cardiomyopathy, pri-
mary arrhythmia (without speciﬁcation), and congenital
heart disease especially in the ≤18 years of age cohort. Since
at the end of their study only 32% of patients had an ICD
implanted, prolonged WCD use might be justiﬁed [14].
4.9. Summary of Reported Prolonged WCD Use. Several pa-
tient populations were reported to use the WCD for an ex-
tended period. Some subgroups weremore prevalent probably
due to the (assumed) reversibility of their elevated arrhyth-
mogenic risk. In general, patients not yet receiving an OMT
deserve a chance to improve their ejection fractionwhile being
protected from SCD events. Patients possibly beneﬁting
prolonged use after review available literature may be patients
with PPCM and young patients in order to avoid unnecessary
ICD implantation. +ese patients may be at higher risk of
dying from SCD than dying of other cause, yet ICD im-
plantation should be carefully evaluated after establishing
OMT.
Clinicians also have to take into account patients’ choice
to refuse ICD while accepting a longer WCD use. +e
prolonged use of WCD in patients with NICM seems less
clear particularly due to low treatment rates reported. +ere
are several disadvantages of a prolonged WCD use. Wear
comfort is an obvious problem especially over longer pe-
riods. +e absence of pacing modalities (for bradycardia,
antitachycardia pacing, or postshock pacing) can be an issue
and fail to prevent SCD due to asystole. Lastly, a cost-beneﬁt
analysis is necessary to justify a longer WCD use.
4.10. Limitations. Our analysis has several limitations. +e
heterogeneity of clinical studies, which resulted in missing
data on the time of appropriate shocks, is a limitation of this
study. 11 of the 14 studies reported the database kept by
ZOLL. It is therefore possible that patients fulﬁlling in-
clusion criteria for more than one of the listed studies in
Table 1 were reported more than once.
5. Conclusions
Extended use of WCD is commonly reported in reviewed
literature, although majority of it is of descriptive nature.
Patients most likely to wear the device longer than 3 months
seem to be patients with NICM, speciﬁcally PPCM likely due
to the lack of other signiﬁcant comorbidities and the high
rate of disease improvement beyond the ﬁrst 3 months often
obviating the need for ICD implantation. On the contrary,
patients listed for heart transplantation could also beneﬁt
from prolonged therapy to avoid risks of the more invasive
ICD implantation. Question remains, however, what the rate
of appropriate shock is during this prolonged use, if a true
beneﬁt is present compared to ICD implantation. To assess
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this true beneﬁt, prospective and randomized data are
needed.
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